{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T12:27:07Z","timestamp":1792153627019,"version":"4.4.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T00:00:00Z","timestamp":1739145600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T00:00:00Z","timestamp":1739145600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmologie"],"DOI":"10.1007\/s00347-025-02197-8","type":"journal-article","created":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T12:16:12Z","timestamp":1739189772000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Sekund\u00e4re chorioidale Neovaskularisation\u00a0\u2013 Wirklich so\u00a0h\u00e4ufig?","Secondary choroidal neovascularization\u2014Really so common?"],"prefix":"10.1007","author":[{"given":"Ulrike","family":"Brocks","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Ziegler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens","family":"Lange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lebriz","family":"Altay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurenz","family":"Pauleikhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,10]]},"reference":[{"key":"2197_CR1","unstructured":"Berufsverband der Augen\u00e4rzte Deutschlands e.\u202fV. (BVA), Deutsche Ophthalmologische Gesellschaft, Retinologische Gesellschaft (2017) Stellungnahme des Berufsverbandes der Augen\u00e4rzte Deutschlands, der Deutschen Ophthalmologischen Gesellschaft und der Retinologischen Gesellschaft zur Therapie chorioidaler Neovaskularisationen bei anderen Erkrankungen als der neovaskul\u00e4ren altersabh\u00e4ngigen Makuladegeneration."},{"key":"2197_CR2","doi-asserted-by":"publisher","first-page":"405","DOI":"10.3928\/15428877-20096030-10","volume":"40","author":"M \u00c7akir","year":"2009","unstructured":"\u00c7akir\u00a0M, \u00c7eki\u00e7\u00a0O, Yilmaz \u00d6F (2009) Photodynamic Therapy for Iatrogenic CNV Due to Laser Photocoagulation in Central Serous Chorioretinopathy. Ophthalmic Surg Lasers Imaging Retina 40:405\u2013408. https:\/\/doi.org\/10.3928\/15428877-20096030-10","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"2197_CR3","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.oret.2017.01.003","volume":"1","author":"A Carnevali","year":"2017","unstructured":"Carnevali\u00a0A, Capuano\u00a0V, Sacconi\u00a0R et\u00a0al (2017) OCT Angiography of Treatment-Na\u00efve Quiescent Choroidal Neovascularization in Pachychoroid Neovasculopathy. Ophthalmol Retina 1:328\u2013332. https:\/\/doi.org\/10.1016\/j.oret.2017.01.003","journal-title":"Ophthalmol Retina"},{"key":"2197_CR4","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1097\/IAE.0000000000000804","volume":"36","author":"J Chhablani","year":"2016","unstructured":"Chhablani\u00a0J, Pichi\u00a0F, Silva\u00a0R et\u00a0al (2016) Antiangiogenics In Choroidal Neovascularization Associated WITH Laser IN Central Serous Chorioretinopathy. Retina 36:901\u2013908. https:\/\/doi.org\/10.1097\/IAE.0000000000000804","journal-title":"Retina"},{"key":"2197_CR5","doi-asserted-by":"publisher","first-page":"128","DOI":"10.3928\/23258160-20160126-05","volume":"47","author":"TE De Carlo","year":"2016","unstructured":"De Carlo\u00a0TE, Rosenblatt\u00a0A, Goldstein\u00a0M et\u00a0al (2016) Vascularization of Irregular Retinal Pigment Epithelial Detachments in Chronic Central Serous Chorioretinopathy Evaluated With OCT Angiography. Ophthalmic Surg Lasers Imaging Retina 47:128\u2013133. https:\/\/doi.org\/10.3928\/23258160-20160126-05","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"2197_CR6","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1001\/archopht.122.1.37","volume":"122","author":"E Ergun","year":"2004","unstructured":"Ergun\u00a0E (2004) Photodynamic Therapy With Verteporfin in Subfoveal Choroidal NeovascularizationSecondary to Central Serous Chorioretinopathy. Arch Ophthalmol 122:37. https:\/\/doi.org\/10.1001\/archopht.122.1.37","journal-title":"Arch Ophthalmol"},{"key":"2197_CR7","doi-asserted-by":"publisher","first-page":"7874","DOI":"10.1167\/iovs.14-14610","volume":"55","author":"M Hata","year":"2014","unstructured":"Hata\u00a0M, Oishi\u00a0A, Tsujikawa\u00a0A et\u00a0al (2014) Efficacy of Intravitreal Injection of Aflibercept in Neovascular Age-Related Macular Degeneration With or Without Choroidal Vascular Hyperpermeability. Invest Ophthalmol Vis Sci 55:7874\u20137880. https:\/\/doi.org\/10.1167\/iovs.14-14610","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2197_CR8","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1097\/IAE.0000000000003067","volume":"41","author":"S Hwang","year":"2021","unstructured":"Hwang\u00a0S, Noh\u00a0H, Kang\u00a0SW et\u00a0al (2021) Choroidal Neovascularization Secondary To Photodynamic Therapy For Central Serous Chorioretinopathy: Incidence, Risk Factors, and Clinical Outcomes. Retina 41:1762\u20131770. https:\/\/doi.org\/10.1097\/IAE.0000000000003067","journal-title":"Retina"},{"key":"2197_CR9","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1097\/IAE.0000000000003615","volume":"42","author":"A Jeong","year":"2022","unstructured":"Jeong\u00a0A, Kang\u00a0W, Sagong\u00a0M (2022) Multimodal Imaging Features And Treatment Responses Of Choroidal Neovascularization Secondary To Central Serous Chorioretinopathy. Retina 42:2326\u20132335. https:\/\/doi.org\/10.1097\/IAE.0000000000003615","journal-title":"Retina"},{"key":"2197_CR10","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1038\/s41598-019-38504-y","volume":"9","author":"BJ Jung","year":"2019","unstructured":"Jung\u00a0BJ, Kim\u00a0JY, Lee\u00a0JH et\u00a0al (2019) Intravitreal aflibercept and ranibizumab for pachychoroid neovasculopathy. Sci Rep 9:2055. https:\/\/doi.org\/10.1038\/s41598-019-38504-y","journal-title":"Sci Rep"},{"key":"2197_CR11","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1007\/s10792-021-01754-9","volume":"41","author":"B Karasu","year":"2021","unstructured":"Karasu\u00a0B, Celebi\u00a0ARC (2021) An efficacy comparison of combination of different anti-vascular endothelial growth factors and photodynamic therapy in patients with pachychoroid neovasculopathy. Int Ophthalmol 41:1989\u20132000. https:\/\/doi.org\/10.1007\/s10792-021-01754-9","journal-title":"Int Ophthalmol"},{"key":"2197_CR12","doi-asserted-by":"publisher","DOI":"10.1111\/aos.16739","author":"HC Kiilgaard","year":"2024","unstructured":"Kiilgaard\u00a0HC, Nissen\u00a0AHK, Balaratnasingam\u00a0C et\u00a0al (2024) Diagnostic accuracy of OCT angiography for macular neovascularization in central serous chorioretinopathy: A\u00a0systematic review and meta-analysis. Acta Ophthalmol. https:\/\/doi.org\/10.1111\/aos.16739","journal-title":"Acta Ophthalmol"},{"key":"2197_CR13","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1007\/s00417-020-04661-4","volume":"258","author":"Y Kitajima","year":"2020","unstructured":"Kitajima\u00a0Y, Maruyama-Inoue\u00a0M, Ito\u00a0A et\u00a0al (2020) One-year outcome of combination therapy with intravitreal anti-vascular endothelial growth factor and photodynamic therapy in patients with pachychoroid neovasculopathy. Graefes Arch Clin Exp Ophthalmol 258:1279\u20131285. https:\/\/doi.org\/10.1007\/s00417-020-04661-4","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2197_CR14","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000001744","author":"TYY Lai","year":"2017","unstructured":"Lai\u00a0TYY, Staurenghi\u00a0G, Lanzetta\u00a0P et\u00a0al (2017) Efficacy And Safety Of Ranibizumab For The Treatment Of Choroidal Neovascularization Due To Uncommon Cause: Twelve-Month Results of the MINERVA Study. Retina. https:\/\/doi.org\/10.1097\/IAE.0000000000001744","journal-title":"Retina"},{"key":"2197_CR15","doi-asserted-by":"publisher","DOI":"10.1159\/000535930","author":"CA Lange","year":"2024","unstructured":"Lange\u00a0CA, Ohlmeier\u00a0C, Kisk\u00e4mper\u00a0A et\u00a0al (2024) Clinical Landscape of Central Serous Chorioretinopathy in Germany\u2014Retina.net CSC Registry Report No 1. Ophthalmologica. https:\/\/doi.org\/10.1159\/000535930","journal-title":"Ophthalmologica"},{"key":"2197_CR16","doi-asserted-by":"publisher","first-page":"3927","DOI":"10.1038\/s41598-019-40406-y","volume":"9","author":"G-I Lee","year":"2019","unstructured":"Lee\u00a0G\u2011I, Kim\u00a0AY, Kang\u00a0SW et\u00a0al (2019) Risk Factors and Outcomes of Choroidal Neovascularization Secondary to Central Serous Chorioretinopathy. Sci Rep 9:3927. https:\/\/doi.org\/10.1038\/s41598-019-40406-y","journal-title":"Sci Rep"},{"key":"2197_CR17","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1097\/00006982-200202000-00004","volume":"22","author":"RH Loo","year":"2002","unstructured":"Loo\u00a0RH, Scott\u00a0IU, Flynn\u00a0HW et\u00a0al (2002) Factors Associated With Reduced Visual Acuity During Long-Term Follow-Up Of Patients With Idiopathic Central Serous Chorioretinopathy. Retina 22:19\u201324. https:\/\/doi.org\/10.1097\/00006982-200202000-00004","journal-title":"Retina"},{"key":"2197_CR18","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s10384-020-00722-7","volume":"64","author":"H Matsumoto","year":"2020","unstructured":"Matsumoto\u00a0H, Mukai\u00a0R, Kikuchi\u00a0Y et\u00a0al (2020) One-year outcomes of half-fluence photodynamic therapy combined with intravitreal injection of aflibercept for pachychoroid neovasculopathy without polypoidal lesions. Jpn J Ophthalmol 64:203\u2013209. https:\/\/doi.org\/10.1007\/s10384-020-00722-7","journal-title":"Jpn J Ophthalmol"},{"key":"2197_CR19","doi-asserted-by":"publisher","first-page":"e0248760","DOI":"10.1371\/journal.pone.0248760","volume":"16","author":"A Miki","year":"2021","unstructured":"Miki\u00a0A, Kusuhara\u00a0S, Otsuji\u00a0T et\u00a0al (2021) Photodynamic therapy combined with anti-vascular endothelial growth factor therapy for pachychoroid neovasculopathy. PLoS ONE 16:e248760. https:\/\/doi.org\/10.1371\/journal.pone.0248760","journal-title":"PLoS ONE"},{"key":"2197_CR20","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.2147\/OPTH.S160956","volume":"12","author":"D Mohabati","year":"2018","unstructured":"Mohabati\u00a0D, van Rijssen\u00a0TJ, van Dijk\u00a0EH et\u00a0al (2018) Clinical characteristics and long-term visual outcome of severe phenotypes of chronic central serous chorioretinopathy. Clin Ophthalmol 12:1061\u20131070. https:\/\/doi.org\/10.2147\/OPTH.S160956","journal-title":"Clin Ophthalmol"},{"key":"2197_CR21","doi-asserted-by":"publisher","first-page":"3191","DOI":"10.1007\/s00417-024-06499-6","volume":"262","author":"Y Nomura","year":"2024","unstructured":"Nomura\u00a0Y, Aoki\u00a0S, Kitamoto\u00a0K et\u00a0al (2024) Three-year outcome of photodynamic therapy combined with VEGF inhibitor for pachychoroid neovasculopathy. Graefes Arch Clin Exp Ophthalmol 262:3191\u20133200. https:\/\/doi.org\/10.1007\/s00417-024-06499-6","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2197_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2023.10.007","author":"LJB Pauleikhoff","year":"2023","unstructured":"Pauleikhoff\u00a0LJB, Diederen\u00a0RMH, Chang-Wolf\u00a0JM et\u00a0al (2023) Choroidal vascular changes on ultra-widefield indocyanine green angiography in central serous chorioretinopathy: CERTAIN study report 1. Ophthalmol Retina. https:\/\/doi.org\/10.1016\/j.oret.2023.10.007","journal-title":"Ophthalmol Retina"},{"key":"2197_CR23","doi-asserted-by":"publisher","DOI":"10.1111\/aos.16679","author":"LJB Pauleikhoff","year":"2024","unstructured":"Pauleikhoff\u00a0LJB, Diederen\u00a0RMH, Chang-Wolf\u00a0JM et\u00a0al (2024) Choroidal hyperpermeability patterns correlate with disease severity in central serous chorioretinopathy: CERTAIN study report 2. Acta Ophthalmol. https:\/\/doi.org\/10.1111\/aos.16679","journal-title":"Acta Ophthalmol"},{"key":"2197_CR24","doi-asserted-by":"publisher","first-page":"3164","DOI":"10.1177\/1120672120986370","volume":"31","author":"G Querques","year":"2021","unstructured":"Querques\u00a0G, Sacconi\u00a0R, Capuano\u00a0V et\u00a0al (2021) Treatment-na\u00efve quiescent macular neovascularization secondary to AMD: The 2019 Young Investigator Lecture of Macula Society. Eur J Ophthalmol 31:3164\u20133176. https:\/\/doi.org\/10.1177\/1120672120986370","journal-title":"Eur J Ophthalmol"},{"key":"2197_CR25","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1136\/bjophthalmol-2019-314625","volume":"104","author":"K Romdhane","year":"2020","unstructured":"Romdhane\u00a0K, Zola\u00a0M, Matet\u00a0A et\u00a0al (2020) Predictors of treatment response to intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy for choroidal neovascularisation secondary to chronic central serous chorioretinopathy. Br J Ophthalmol 104:910\u2013916. https:\/\/doi.org\/10.1136\/bjophthalmol-2019-314625","journal-title":"Br J Ophthalmol"},{"key":"2197_CR26","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1007\/s00417-020-04623-w","volume":"258","author":"B Schworm","year":"2020","unstructured":"Schworm\u00a0B, Luft\u00a0N, Keidel\u00a0LF et\u00a0al (2020) Response of neovascular central serous chorioretinopathy to an extended upload of anti-VEGF agents. Graefes Arch Clin Exp Ophthalmol 258:1013\u20131021. https:\/\/doi.org\/10.1007\/s00417-020-04623-w","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2197_CR27","doi-asserted-by":"publisher","first-page":"8439","DOI":"10.1038\/s41598-020-65370-w","volume":"10","author":"B Schworm","year":"2020","unstructured":"Schworm\u00a0B, Luft\u00a0N, Keidel\u00a0LF et\u00a0al (2020) Ranibizumab non-response in pachychoroid neovasculopathy: Effects of switching to aflibercept. Sci Rep 10:8439. https:\/\/doi.org\/10.1038\/s41598-020-65370-w","journal-title":"Sci Rep"},{"key":"2197_CR28","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.3390\/jcm11051443","volume":"11","author":"R Serra","year":"2022","unstructured":"Serra\u00a0R, Pinna\u00a0A, Behar-Cohen\u00a0F, Coscas\u00a0F (2022) OCT Angiography Fractal Analysis of Choroidal Neovessels Secondary to Central Serous Chorioretinopathy, in a\u00a0Caucasian Cohort. J\u00a0Clin Med 11:1443. https:\/\/doi.org\/10.3390\/jcm11051443","journal-title":"J Clin Med"},{"key":"2197_CR29","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.ajo.2018.06.009","volume":"193","author":"C Shiragami","year":"2018","unstructured":"Shiragami\u00a0C, Takasago\u00a0Y, Osaka\u00a0R et\u00a0al (2018) Clinical Features of Central Serous Chorioretinopathy With Type\u00a01 Choroidal Neovascularization. Am J Ophthalmol 193:80\u201386. https:\/\/doi.org\/10.1016\/j.ajo.2018.06.009","journal-title":"Am J Ophthalmol"},{"key":"2197_CR30","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1038\/eye.2016.41","volume":"30","author":"E Smretschnig","year":"2016","unstructured":"Smretschnig\u00a0E, Hagen\u00a0S, Glittenberg\u00a0C et\u00a0al (2016) Intravitreal anti-vascular endothelial growth factor combined with half-fluence photodynamic therapy for choroidal neovascularization in chronic central serous chorioretinopathy. Eye Lond Engl 30:805\u2013811. https:\/\/doi.org\/10.1038\/eye.2016.41","journal-title":"Eye Lond Engl"},{"key":"2197_CR31","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.ophtha.2017.12.002","volume":"125","author":"G Staurenghi","year":"2018","unstructured":"Staurenghi\u00a0G, Lai\u00a0TYY, Mitchell\u00a0P et\u00a0al (2018) Efficacy and Safety of Ranibizumab 0.5\u202fmg for the Treatment of Macular Edema Resulting from Uncommon Causes. Ophthalmology 125:850\u2013862. https:\/\/doi.org\/10.1016\/j.ophtha.2017.12.002","journal-title":"Ophthalmology"},{"key":"2197_CR32","doi-asserted-by":"publisher","first-page":"7217906","DOI":"10.1155\/2020\/7217906","volume":"2020","author":"JH Yeo","year":"2020","unstructured":"Yeo\u00a0JH, Oh\u00a0R, Kim\u00a0YJ et\u00a0al (2020) Choroidal Neovascularization Secondary to Central Serous Chorioretinopathy: OCT Angiography Findings and Risk Factors. J\u00a0Ophthalmol 2020:7217906. https:\/\/doi.org\/10.1155\/2020\/7217906","journal-title":"J Ophthalmol"},{"key":"2197_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2022\/1272524","volume":"2022","author":"Y Zhang","year":"2022","unstructured":"Zhang\u00a0Y, Zhang\u00a0J, Sun\u00a0X (2022) The Efficacy of Anti-VEGF Therapy for Putative or Visible CNV in Central Serous Chorioretinopathy by Optical Coherence Tomography Angiography. J\u00a0Ophthalmol 2022:1\u201311. https:\/\/doi.org\/10.1155\/2022\/1272524","journal-title":"J Ophthalmol"}],"container-title":["Die Ophthalmologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-025-02197-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00347-025-02197-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-025-02197-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T12:16:19Z","timestamp":1739189779000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00347-025-02197-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,10]]},"references-count":33,"alternative-id":["2197"],"URL":"https:\/\/doi.org\/10.1007\/s00347-025-02197-8","relation":{},"ISSN":["2731-720X","2731-7218"],"issn-type":[{"value":"2731-720X","type":"print"},{"value":"2731-7218","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,10]]},"assertion":[{"value":"12 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"U.\u00a0Brocks, M.\u00a0Ziegler, C.\u00a0Lange, L.\u00a0Altay und L.\u00a0Pauleikhoff geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}